开始
RocketTickers

FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic

做多
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)  
RocketTickers  
NASDAQ:REGN   Regeneron Pharmaceuticals, Inc.
Beyond Technical Analysis
0
0
beyondta
REGN: Regeneron Pharmaceuticals, Inc.
2019-03-11 15:44:00
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents - PR Newswire
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。